Pharmazell Group Revenue and Competitors

Raubling,

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Pharmazell Group's estimated annual revenue is currently $77.4M per year.(i)
  • Pharmazell Group's estimated revenue per employee is $201,000

Employee Data

  • Pharmazell Group has 385 Employees.(i)
  • Pharmazell Group grew their employee count by 2% last year.

Pharmazell Group's People

NameTitleEmail/Phone
1
Production ManagerReveal Email/Phone
2
SAP Inhouse Consultant Financials, BOReveal Email/Phone
3
General ManagerReveal Email/Phone
4
ProjektingenieurReveal Email/Phone
5
Chemie MeisterReveal Email/Phone
6
SAP Basis-AdministratorReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$46.2M2305%N/AN/A
#2
$43.8M21821%N/AN/A
#3
$57.1M28426%N/AN/A
#4
$24.5M1223%N/AN/A
#5
$52.9M26313%N/AN/A
#6
$24.7M12313%N/AN/A
#7
$1.8M180%$114.3MN/A
#8
$7.2M36-20%N/AN/A
#9
$13.7M68-7%N/AN/A
#10
$7.6M39-13%$123.9MN/A
Add Company

What Is Pharmazell Group?

PharmaZell offers a focused portfolio of small molecule APIs, together with custom development and manufacturing services for the generic and originator pharmaceutical industry. The company operates at three production sites, one in Germany and two in India. As part of the PharmaZell Group, the company employs 750 employees worldwide.

keywords:N/A

N/A

Total Funding

385

Number of Employees

$77.4M

Revenue (est)

2%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Pharmazell Group News

2022-04-17 - Chenodeoxycholic Acid Market Will Reflect Significant Growth ...

ICE Group, Zhongshan Belling Biotechnology, Suzhou Tianlu Bio-pharmaceutical, PharmaZell GmbH, Daewoong, Linyi Tianli Biochemical,...

2022-04-06 - PharmaZell, Novasep merger creates new CDMO, API ...

PharmaZell, Novasep merger creates new CDMO, API manufacturer ... He said, “I have great confidence that the group will become a major...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$160.8M52514%N/A
#2
$122.4M60920%N/A